New survey: 70% of women with an autoimmune condition say it's limited their career potential. Its study, conducted in partnership with the Autoimmune Association, shines light on the hidden costs of chronic illness for women and their employers. 80% of individuals diagnosed with autoimmune diseases are women - and for many, their condition impacts not just their health, but their career trajectory. WellTheory Technologies, Inc. partnered with the Autoimmune Association to conduct a national survey of 250 U.S. working women with autoimmune diseases. The findings, released during Autoimmune Awareness Month, reveal how autoimmune disease is quietly reshaping the workplace - and the urgent need for care models that better support those with chronic conditions. Stalled careers, lost potential. 70% of working women with an autoimmune condition say that their career potential has suffered, and 68% report they've experienced negative effects at work since being diagnosed. Among these women: These numbers highlight the difficult decisions many women face when balancing the demands of a job and a chronic condition - and how the trade-offs can impact their careers long-term. Women are carrying an invisible burden. Autoimmune symptoms can take a toll on women's day-to-day lives, with 61% saying that their symptoms impact their ability to function at work every day or most days. They're living with symptoms like chronic pain, fatigue, and brain fog, yet 61% have chosen not to disclose their autoimmune condition to their employer. Fear of being judged (32%), concern about being passed over for opportunities (28%), or simply believing that telling their employer about their condition won't help (41%) are keeping women silent - and keeping employers in the dark. Managing a chronic health condition comes with a cost. For many women with autoimmune diseases, career decisions aren't just about growth - they're about survival. 68% have stayed at a job because they needed health insurance, and 76% reported experiencing financial strain due to their condition. But autoimmune conditions cost employers, too - contributing to employee absenteeism, reduced productivity, and driving 50% of specialty drug spend. With autoimmune diagnoses on the rise, it's becoming increasingly important to address chronic care models across the workforce. Women shouldn't have to choose between their career and their health. Autoimmune diseases require personalized care, yet many women are left navigating fragmented systems that prioritize short-term symptom management over long-term results. "When women receive consistent, specialized autoimmune care, they don't have to sacrifice their careers for their health," says Ellen Rudolph, CEO and Co-Founder of WellTheory. "We work alongside employers to provide that support, helping women manage chronic symptoms while staying on their chosen professional paths." Its evidence-based care model provides members with ongoing clinical guidance and personalized support to help reduce symptom disruptions at work. Outcomes show improvements in physical and mental health, workplace productivity, and lower costs - proof that when women with autoimmune conditions get the support they need, everyone benefits.

WellTheory Technologies, Inc. just raised a $14M Series A led by General Catalyst. Here's what's next for autoimmune care. WellTheory raised $14M in Series A funding led by General Catalyst to expand its personalized, women-led approach to reimagining autoimmune care for millions of patients. Today marks a new chapter for WellTheory - and for the millions of Americans living with autoimmune disease. WellTheory Technologies, Inc. is proud to announce its $14M Series A funding led by General Catalyst, with participation from 7wire Ventures, Ingeborg Investments, Accel, Box Group, and Up2 Opportunity Fund. This milestone means so much more than funding. It's proof that the world is starting to pay attention to an epidemic that's been ignored for far too long. The growing autoimmune crisis. Autoimmune disease affects over 50 million Americans, 80% of whom are women. Yet for decades, it's been misunderstood, underdiagnosed, and overlooked. These conditions are rising faster than any other disease category, doubling in prevalence in just 30 years. The costs are staggering. Autoimmune disease now represents a $150B+ annual market, a figure that continues to climb as new immunology drugs come to market. These conditions account for 50% of all specialty drug spend, which has risen 459% over the past decade. Employers and health plans feel this burden acutely, but autoimmune diseases are often invisible in claims data - scattered across specialties, never tied back to the same root cause. Behind those numbers are real people. People who have spent years searching for answers, only to be told their labs look "normal" or that their symptoms are "all in their head." From personal stories to a shared mission. At 25, I was bedridden and desperate for answers. I spent months cycling through specialists and tests, hoping someone would finally connect the dots. When I was eventually diagnosed with an autoimmune condition, I realized just how broken the system was and how many others were being left behind. Along the way, I connected with my co-founders, Claire and Wallace, whose lives had also been touched by autoimmune disease. Together, WellTheory Technologies, Inc. decided to build the solution WellTheory Technologies, Inc. all wished had existed at the start of its journeys - care that's personalized, proactive, and rooted in compassion. When WellTheory Technologies, Inc. launched WellTheory, its goal was simple but ambitious: to reimagine autoimmune care from the ground up with a model that looks at the whole person, not just the diagnosis. What started as a small, passionate community has grown into something much larger. Today, WellTheory Technologies, Inc. is seeing thousands of members reduce symptoms, regain energy, and rebuild their lives after years of being dismissed. Employers and health plans are also recognizing what patients have known all along: autoimmune conditions can't be treated in silos. They're now turning to WellTheory to address autoimmune conditions at scale - not as isolated diseases, but as systemic issues affecting every aspect of well-being and productivity. Built & backed by women: defying the odds. As a woman living with autoimmune disease, I've spent years navigating systems that weren't built for patients like me - or founders like me, either. Less than 2% of venture capital goes to women. Only 17% of VC decision-makers are women. And women's health continues to be chronically underfunded. That's why this round feels especially meaningful and why I couldn't be prouder that its cap table reflects the patients WellTheory Technologies, Inc. serve. When I met Candace and Holly from General Catalyst, I knew I'd found partners who truly understood. Both had personal connections to autoimmune disease - they'd seen the toll it takes on people they love. They believed in this mission not just as investors, but as women who have seen the system fail people they love and who want to change it. I'm also grateful to have Alyssa and Tiffany from 7wire Ventures and Anna and Mira from Ingeborg Investments joining this mission - women who share its conviction that health equity and access go hand in hand. Together, WellTheory Technologies, Inc. is showing what happens when women build, back, and lead in healthcare, and it feels like WellTheory Technologies, Inc. is building the system WellTheory Technologies, Inc. has always deserved to see. What's ahead. In just the last year, WellTheory has grown more than 10x in membership and partnered with visionary employers and payors like Fortune Brands, Dayforce, and Sentara Health Plans. WellTheory Technologies, Inc. has built proprietary AI tools - Care Hub and Care Scribe - to help its care teams personalize support and improve health outcomes at scale. * Deepen partnerships with employers and health plans * Expand its care programs to reach more people and conditions * Accelerate AI development to make its care even more personalized and accessible WellTheory Technologies, Inc. is investing in technology, clinical research, and enterprise expansion to bring this model to millions - because addressing autoimmune disease isn't just about managing symptoms; it's about redefining what care can look like. P.S. WellTheory Technologies, Inc. is growing fast and hiring across teams. If you feel called to its mission and driven by grit, resilience, and a belief that change happens when people refuse to accept the status quo - WellTheory Technologies, Inc.'d love to meet you.